SHR-1918 / Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SHR-1918 / Jiangsu Hengrui Pharma
NCT06723652: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Recruiting
3
45
RoW
SHR-1918, SHR-1918 placebo
Beijing Suncadia Pharmaceuticals Co., Ltd
Homozygous Familial Hypercholesterolemia
05/25
12/25
NCT06009393: Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Not yet recruiting
2
20
NA
SHR-1918
Beijing Suncadia Pharmaceuticals Co., Ltd
Homozygous Familial Hypercholesterolemia
06/24
08/24
NCT06471218: Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Active, not recruiting
2
44
RoW
SHR-1918; SHR-1918 Placebo
Beijing Suncadia Pharmaceuticals Co., Ltd
Hyperlipidemia
04/25
06/25
NCT06109831: Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

Active, not recruiting
2
335
RoW
SHR-1918, SHR-1918 placebo
Beijing Suncadia Pharmaceuticals Co., Ltd
Hyperlipidemic
10/24
09/25
ChiCTR2200066760: Safety, tolerability, pharmacokinetic and pharmacodynamic profiles of a single subcutaneous injection of SHR-1918 in healthy subjects - a randomized, double-blind, dose-escalating, placebo-controlled phase I clinical trial

Not yet recruiting
1
72
 
SHR-1918 Injection (dosage 1) vs placebo ;SHR-1918 Injection (dosage 2) vs placebo ;SHR-1918 Injection (dosage 3) vs placebo ;SHR-1918 Injection (dosage 4) vs placebo ;SHR-1918 Injection (dosage 5) vs placebo（selective） ;SHR-1918 Injection (dosage 6) vs placebo (selective）
The second hospital of Anhui Medical University; Beijing Shengdi Pharmaceutical Co., LTD, Beijing Shengdi Pharmaceutical Co., LTD
Hypercholesterolemia
 
 
NCT05432544: Safety and Tolerability of SHR-1918 in Healthy Subjects

Active, not recruiting
1
72
RoW
SHR-1918, SHR-1918 placebo
Beijing Suncadia Pharmaceuticals Co., Ltd
Hyperlipemia
12/23
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SHR-1918 / Jiangsu Hengrui Pharma
NCT06723652: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Recruiting
3
45
RoW
SHR-1918, SHR-1918 placebo
Beijing Suncadia Pharmaceuticals Co., Ltd
Homozygous Familial Hypercholesterolemia
05/25
12/25
NCT06009393: Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

Not yet recruiting
2
20
NA
SHR-1918
Beijing Suncadia Pharmaceuticals Co., Ltd
Homozygous Familial Hypercholesterolemia
06/24
08/24
NCT06471218: Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

Active, not recruiting
2
44
RoW
SHR-1918; SHR-1918 Placebo
Beijing Suncadia Pharmaceuticals Co., Ltd
Hyperlipidemia
04/25
06/25
NCT06109831: Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

Active, not recruiting
2
335
RoW
SHR-1918, SHR-1918 placebo
Beijing Suncadia Pharmaceuticals Co., Ltd
Hyperlipidemic
10/24
09/25
ChiCTR2200066760: Safety, tolerability, pharmacokinetic and pharmacodynamic profiles of a single subcutaneous injection of SHR-1918 in healthy subjects - a randomized, double-blind, dose-escalating, placebo-controlled phase I clinical trial

Not yet recruiting
1
72
 
SHR-1918 Injection (dosage 1) vs placebo ;SHR-1918 Injection (dosage 2) vs placebo ;SHR-1918 Injection (dosage 3) vs placebo ;SHR-1918 Injection (dosage 4) vs placebo ;SHR-1918 Injection (dosage 5) vs placebo（selective） ;SHR-1918 Injection (dosage 6) vs placebo (selective）
The second hospital of Anhui Medical University; Beijing Shengdi Pharmaceutical Co., LTD, Beijing Shengdi Pharmaceutical Co., LTD
Hypercholesterolemia
 
 
NCT05432544: Safety and Tolerability of SHR-1918 in Healthy Subjects

Active, not recruiting
1
72
RoW
SHR-1918, SHR-1918 placebo
Beijing Suncadia Pharmaceuticals Co., Ltd
Hyperlipemia
12/23
12/23

Download Options